Partial Thromboplastin Time

"Partial Thromboplastin Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.

Descriptor ID	D010314
MeSH Number(s)	E01.370.225.625.115.600 E05.200.625.115.600 G09.188.660
Concept/Terms	Partial Thromboplastin Time Partial Thromboplastin Time Thromboplastin Time, Partial Activated Partial Thromboplastin Time Kaolin-Cephalin Coagulation Time Kaolin-Cephalin Coagulation Time Coagulation Time, Kaolin-Cephalin Kaolin Cephalin Coagulation Time Coagulation Time, Cephalin-Kaolin Coagulation Time, Cephalin Kaolin Cephalin-Kaolin Coagulation Time Cephalin Kaolin Coagulation Time

Below are MeSH descriptors whose meaning is more general than "Partial Thromboplastin Time".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Hematologic Tests [E01.370.225.625]
Blood Coagulation Tests [E01.370.225.625.115]
Partial Thromboplastin Time [E01.370.225.625.115.600]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Hematologic Tests [E05.200.625]
Blood Coagulation Tests [E05.200.625.115]
Partial Thromboplastin Time [E05.200.625.115.600]
Biological Sciences [G]
Circulatory and Respiratory Physiological Phenomena [G09]
Blood Physiological Phenomena [G09.188]
Partial Thromboplastin Time [G09.188.660]

Below are MeSH descriptors whose meaning is more specific than "Partial Thromboplastin Time".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Partial Thromboplastin Time" by people in this website by year, and whether "Partial Thromboplastin Time" was a major or minor topic of these publications.

Bar chart showing 6 publications over 6 distinct years, with a maximum of 1 publications in 2002 and 2008 and 2012 and 2013 and 2017 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2008	0	1	1
2012	0	1	1
2013	0	1	1
2017	0	1	1
2020	1	0	1

Below are the most recent publications written about "Partial Thromboplastin Time" by people in Profiles.

Lawlor M, Gupta A, Ranard LS, Madhavan MV, Li J, Eisenberger A, Parikh SA, Sethi SS, Masoumi A. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thromb Res. 2021 02; 198:79-82.

View in: PubMed
Hsieh CC, Cia CT, Lee JC, Sung JM, Lee NY, Chen PL, Kuo TH, Chao JY, Ko WC. A Cohort Study of Adult Patients with Severe Dengue in Taiwanese Intensive Care Units: The Elderly and APTT Prolongation Matter for Prognosis. PLoS Negl Trop Dis. 2017 01; 11(1):e0005270.

View in: PubMed
Naik BI, Durieux ME, Knisely A, Sharma J, Bui-Huynh VC, Yalamuru B, Terkawi AS, Nemergut EC. SEER Sonorheometry Versus Rotational Thromboelastometry in Large Volume Blood Loss Spine Surgery. Anesth Analg. 2016 12; 123(6):1380-1389.

View in: PubMed
Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, Rodriquez D, Weinstein S. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med. 2014 Feb; 15(2):e72-9.

View in: PubMed
Lalama J, Lewis PM, Gore J, Tran MT, Donovan J. How one academic medical center has managed potency changes with unfractionated heparin. J Thromb Thrombolysis. 2013 Jul; 36(1):91-5.

View in: PubMed
Li E, Greenberg PB, Tseng V, Woodmansee SB, Caffrey AR, Wu WC, Friedmann PD, Laplante KL. In vitro coagulation effects of ophthalmic doses of bevacizumab. J Ocul Pharmacol Ther. 2012 Jun; 28(3):219-21.

View in: PubMed
Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011 Dec; 7(4):281-7.

View in: PubMed
Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol. 2008 Oct 01; 102(7):842-6.

View in: PubMed
Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):887S-968S.

View in: PubMed
Sandoval C, Dong S, Visintainer P, Ozkaynak MF, Jayabose S. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol. 2002 Jan; 24(1):47-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals